Chronic obstructive pulmonary disease

The Lancet

Volumn 389, Issue 10082, 2017, Pages 1931-1940

  Rabe, Klaus F ^a,b   Watz, Henrik ^a  

^a GERMAN CENTER FOR LUNG RESEARCH   (Germany)

^b UNIVERSITY OF KIEL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; FLUTICASONE PROPIONATE PLUS SALMETEROL; FUEL; GLYCOPYRRONIUM BROMIDE PLUS INDACATEROL; MACROLIDE; MUSCARINIC RECEPTOR BLOCKING AGENT; OXYGEN; PNEUMOCOCCUS VACCINE;

AIRWAY EPITHELIUM CELL; BIOMASS; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL (TOPIC); COMORBIDITY; DISEASE EXACERBATION; ENVIRONMENTAL EXPOSURE; HUMAN; INFLAMMATION; INFLUENZA VACCINATION; MONOTHERAPY; PATHOPHYSIOLOGY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PULMONARY REHABILITATION; REVIEW; SMOKING CESSATION; SMOKING CESSATION PROGRAM; X-RAY COMPUTED TOMOGRAPHY;

HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 85018884308     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(17)31222-9     Document Type: Review

References (141)

1. Martinez, FD, Early-life origins of chronic obstructive pulmonary disease. N Engl J Med 375 (2016), 871–878.
2. Chapman, KR, Burdon, JG, Piitulainen, E, et al. Intravenous augmentation treatment and lung density in severe alpha1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial. Lancet 386 (2015), 360–368.
3. Wedzicha, JA, Banerji, D, Chapman, KR, et al. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N Engl J Med 374 (2016), 2222–2234.
4. Pascoe, SJ, Lipson, DA, Locantore, N, et al. A phase III randomised controlled trial of single-dose triple therapy in COPD: the IMPACT protocol. Eur Respir J 48 (2016), 320–330.
5. GOLD 2017 Global Strategy for the Diagnosis, Management and Prevention of COPD. http://goldcopd.org/gold-2017-global-strategy-diagnosis-management-prevention-copd/ (accessed Nov 26, 2016).
6. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 388 (2016), 1545–1602.
7. Adeloye, D, Chua, S, Lee, C, et al. Global and regional estimates of COPD prevalence: systematic review and meta-analysis. J Glob Health, 5, 2015, 020415.
8. Gershon, AS, Warner, L, Cascagnette, P, Victor, JC, To, T, Lifetime risk of developing chronic obstructive pulmonary disease: a longitudinal population study. Lancet 378 (2011), 991–996.
9. Lamprecht, B, Soriano, JB, Studnicka, M, et al. Determinants of underdiagnosis of COPD in national and international surveys. Chest 148 (2015), 971–985.
10. World Health Organization. Chronic respiratory diseases. Burden of COPD. http://www.who.int/respiratory/copd/burden/en/ (accessed Nov 19, 2016).
11. Han, MK, Postma, D, Mannino, DM, et al. Gender and chronic obstructive pulmonary disease: why it matters. Am J Respir Crit Care Med 176 (2007), 1179–1184.
12. Sorheim, IC, Johannessen, A, Gulsvik, A, Bakke, PS, Silverman, EK, DeMeo, DL, Gender differences in COPD: are women more susceptible to smoking effects than men?. Thorax 65 (2010), 480–485.
13. Luoto, JA, Elmstahl, S, Wollmer, P, Pihlsgard, M, Incidence of airflow limitation in subjects 65-100 years of age. Eur Respir J 47 (2016), 461–472.
14. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 388 (2016), 1459–1544.
15. Anthonisen, NR, Skeans, MA, Wise, RA, Manfreda, J, Kanner, RE, Connett, JE, The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med 142 (2005), 233–239.
16. Calverley, PM, Anderson, JA, Celli, B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 356 (2007), 775–789.
17. Franssen, FM, Soriano, JB, Roche, N, et al. Lung function abnormalities in smokers with ischemic heart disease. Am J Respir Crit Care Med 194 (2016), 568–576.
18. Burney, PG, Patel, J, Newson, R, Minelli, C, Naghavi, M, Global and regional trends in COPD mortality, 1990–2010. Eur Respir J 45 (2015), 1239–1247.
19. Mannino, DM, Buist, AS, Global burden of COPD: risk factors, prevalence, and future trends. Lancet 370 (2007), 765–773.
20. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 388 (2016), 1659–1724.
21. WHO. Global Health Observatory data. Prevalence of tobacco smoking. http://www.who.int/gho/tobacco/use/en/ (accessed Feb 5, 2017).
22. WHO. World Health statistics 2016 data visualizations dashboard. Tobacco control. Region data. http://apps.who.int/gho/data/view.sdg.3-a-data-reg?lang=en (accessed Feb 5, 2017).
23. Salvi, SS, Barnes, PJ, Chronic obstructive pulmonary disease in non-smokers. Lancet 374 (2009), 733–743.
24. Celli, BR, Decramer, M, Wedzicha, JA, et al. An official American Thoracic Society/European Respiratory Society statement: research questions in COPD. Eur Respir Rev 24 (2015), 159–172.
25. Ramirez-Venegas, A, Sansores, RH, Quintana-Carrillo, RH, et al. FEV1 decline in patients with chronic obstructive pulmonary disease associated with biomass exposure. Am J Respir Crit Care Med 190 (2014), 996–1002.
26. O'Donnell, DE, Hyperinflation, dyspnea, and exercise intolerance in chronic obstructive pulmonary disease. Proc Am Thorac Soc 3 (2006), 180–184.
27. Regan, EA, Lynch, DA, Curran-Everett, D, et al. Clinical and radiologic disease in smokers with normal spirometry. JAMA Intern Med 175 (2015), 1539–1549.
28. Woodruff, PG, Barr, RG, Bleecker, E, et al. Clinical significance of symptoms in smokers with preserved pulmonary function. N Engl J Med 374 (2016), 1811–1821.
29. Obeidat, M, Hao, K, Bosse, Y, et al. Molecular mechanisms underlying variations in lung function: a systems genetics analysis. Lancet Respir Med 3 (2015), 782–795.
30. Wain, LV, Shrine, N, Miller, S, et al. Novel insights into the genetics of smoking behaviour, lung function, and chronic obstructive pulmonary disease (UK BiLEVE): a genetic association study in UK Biobank. Lancet Respir Med 3 (2015), 769–781.
31. Brusselle, GG, Bracke, KR, Elucidating COPD pathogenesis by large-scale genetic analyses. Lancet Respir Med 3 (2015), 737–739.
32. O'Donnell, DE, Neder, JA, Elbehairy, AF, Physiological impairment in mild COPD. Respirology 21 (2016), 211–223.
33. Decramer, M, Janssens, W, Miravitlles, M, Chronic obstructive pulmonary disease. Lancet 379 (2012), 1341–1351.
34. Hurst, JR, Elborn, JS, De Soyza, A, COPD-bronchiectasis overlap syndrome. Eur Respir J 45 (2015), 310–313.
35. McDonough, JE, Yuan, R, Suzuki, M, et al. Small-airway obstruction and emphysema in chronic obstructive pulmonary disease. N Engl J Med 365 (2011), 1567–1575.
36. Lange, P, Celli, B, Agusti, A, et al. Lung-function trajectories leading to chronic obstructive pulmonary disease. N Engl J Med 373 (2015), 111–122.
37. Fuchs, O, Bahmer, T, Rabe, KF, von Mutius, E, Asthma transition from childhood into adulthood. Lancet Respir Med, 2016 published online Sept 22 http://dx.doi.org/10.1016/S2213-2600(16)30187-4.
38. Postma, DS, Rabe, KF, The asthma-COPD overlap syndrome. N Engl J Med 373 (2015), 1241–1249.
39. Demedts, IK, Bracke, KR, Van Pottelberge, G, et al. Accumulation of dendritic cells and increased CCL20 levels in the airways of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 175 (2007), 998–1005.
40. Barnes, PJ, Shapiro, SD, Pauwels, RA, Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J 22 (2003), 672–688.
41. Brusselle, GG, Joos, GF, Bracke, KR, New insights into the immunology of chronic obstructive pulmonary disease. Lancet 378 (2011), 1015–1026.
42. Sullivan, AK, Simonian, PL, Falta, MT, et al. Oligoclonal CD4+ T cells in the lungs of patients with severe emphysema. Am J Respir Crit Care Med 172 (2005), 590–596.
43. van der Strate, BW, Postma, DS, Brandsma, CA, et al. Cigarette smoke-induced emphysema: a role for the B cell?. Am J Respir Crit Care Med 173 (2006), 751–758.
44. MacNee, W, Tuder, RM, New paradigms in the pathogenesis of chronic obstructive pulmonary disease I. Proc Am Thorac Soc 6 (2009), 527–531.
45. Tsuji, T, Aoshiba, K, Nagai, A, Alveolar cell senescence in patients with pulmonary emphysema. Am J Respir Crit Care Med 174 (2006), 886–893.
46. Tsuji, T, Aoshiba, K, Nagai, A, Cigarette smoke induces senescence in alveolar epithelial cells. Am J Respir Cell Mol Biol 31 (2004), 643–649.
47. Mercado, N, Ito, K, Barnes, PJ, Accelerated ageing of the lung in COPD: new concepts. Thorax 70 (2015), 482–489.
48. Hoffman, EA, Lynch, DA, Barr, RG, van Beek, EJ, Parraga, G, Pulmonary CT and MRI phenotypes that help explain chronic pulmonary obstruction disease pathophysiology and outcomes. J Magn Reson Imaging 43 (2016), 544–557.
49. Lynch, DA, Austin, JH, Hogg, JC, et al. CT-definable subtypes of chronic obstructive pulmonary disease: a statement of the Fleischner Society. Radiology 277 (2015), 192–205.
50. Nussbaumer-Ochsner, Y, Rabe, KF, Systemic manifestations of COPD. Chest 139 (2011), 165–173.
51. Decramer, M, Janssens, W, Chronic obstructive pulmonary disease and comorbidities. Lancet Respir Med 1 (2013), 73–83.
52. Vanfleteren, LE, Spruit, MA, Wouters, EF, Franssen, FM, Management of chronic obstructive pulmonary disease beyond the lungs. Lancet Respir Med 4 (2016), 911–924.
53. Chen, W, Thomas, J, Sadatsafavi, M, FitzGerald, JM, Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Lancet Respir Med 3 (2015), 631–639.
54. Roversi, S, Fabbri, LM, Sin, DD, Hawkins, NM, Agusti, A, Chronic obstructive pulmonary disease and cardiac diseases: an urgent need for integrated care. Am J Respir Crit Care Med 194 (2016), 1319–1336.
55. Houghton, AM, Mouded, M, Shapiro, SD, Common origins of lung cancer and COPD. Nat Med 14 (2008), 1023–1024.
56. Houghton, AM, Mechanistic links between COPD and lung cancer. Nat Rev Cancer 13 (2013), 233–245.
57. Durham, AL, Adcock, IM, The relationship between COPD and lung cancer. Lung Cancer 90 (2015), 121–127.
58. de Torres, JP, Marin, JM, Casanova, C, et al. Identification of COPD patients at high risk for lung cancer mortality using the COPD-LUCSS-DLCO. Chest 149 (2016), 936–942.
59. de Torres, JP, Wilson, DO, Sanchez-Salcedo, P, et al. Lung cancer in patients with chronic obstructive pulmonary disease. Development and validation of the COPD Lung Cancer Screening Score. Am J Respir Crit Care Med 191 (2015), 285–291.
60. de Torres, JP, Marin, JM, Casanova, C, Cote, C, et al. Lung cancer in patients with chronic obstructive pulmonary disease—incidence and predicting factors. Am J Respir Crit Care Med 184 (2011), 913–919.
61. de Torres, JP, Bastarrika, G, Wisnivesky, JP, et al. Assessing the relationship between lung cancer risk and emphysema detected on low-dose CT of the chest. Chest 132 (2007), 1932–1938.
62. Sanchez-Salcedo, P, Wilson, DO, de Torres, JP, et al. Improving selection criteria for lung cancer screening. The potential role of emphysema. Am J Respir Crit Care Med 191 (2015), 924–931.
63. Vanfleteren, LE, Spruit, MA, Groenen, M, et al. Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 187 (2013), 728–735.
64. Watz, H, Waschki, B, Kirsten, A, et al. The metabolic syndrome in patients with chronic bronchitis and COPD: frequency and associated consequences for systemic inflammation and physical inactivity. Chest 136 (2009), 1039–1046.
65. McAllister, DA, Maclay, JD, Mills, NL, et al. Arterial stiffness is independently associated with emphysema severity in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 176 (2007), 1208–1214.
66. Houben-Wilke, S, Jorres, RA, Bals, R, et al. Peripheral artery disease and its clinical relevance in patients with chronic obstructive pulmonary disease in the COPD and Systemic Consequences–Comorbidities Network Study. Am J Respir Crit Care Med 195 (2017), 189–197.
67. Williams, MC, Murchison, JT, Edwards, LD, et al. Coronary artery calcification is increased in patients with COPD and associated with increased morbidity and mortality. Thorax 69 (2014), 718–723.
68. Young, RP, Duan, F, Chiles, C, et al. Airflow limitation and histology shift in the National Lung Screening Trial. The NLST-ACRIN Cohort Substudy. Am J Respir Crit Care Med 192 (2015), 1060–1067.
69. Scanlon, PD, Connett, JE, Waller, LA, Altose, MD, Bailey, WC, Buist, AS, Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study. Am J Respir Crit Care Med 161 (2000), 381–390.
70. Jimenez-Ruiz, CA, Andreas, S, Lewis, KE, et al. Statement on smoking cessation in COPD and other pulmonary diseases and in smokers with comorbidities who find it difficult to quit. Eur Respir J 46 (2015), 61–79.
71. Romieu, I, Riojas-Rodriguez, H, Marron-Mares, AT, Schilmann, A, Perez-Padilla, R, Masera, O, Improved biomass stove intervention in rural Mexico: impact on the respiratory health of women. Am J Respir Crit Care Med 180 (2009), 649–656.
72. Hoogendoorn, M, Feenstra, TL, Hoogenveen, RT, Rutten-van Molken, MP, Long-term effectiveness and cost-effectiveness of smoking cessation interventions in patients with COPD. Thorax 65 (2010), 711–718.
73. Poole, PJ, Chacko, E, Wood-Baker, RW, Cates, CJ, Influenza vaccine for patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev, 2006 CD002733.
74. Walters, JA, Smith, S, Poole, P, Granger, RH, Wood-Baker, R, Injectable vaccines for preventing pneumococcal infection in patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev, 2010 CD001390.
75. Garcia-Aymerich, J, Lange, P, Benet, M, Schnohr, P, Anto, JM, Regular physical activity reduces hospital admission and mortality in chronic obstructive pulmonary disease: a population based cohort study. Thorax 61 (2006), 772–778.
76. Waschki, B, Kirsten, AM, Holz, O, et al. Disease progression and changes in physical activity in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 192 (2015), 295–306.
77. Waschki, B, Kirsten, A, Holz, O, et al. Physical activity is the strongest predictor of all-cause mortality in patients with COPD: a prospective cohort study. Chest 140 (2011), 331–342.
78. Watz, H, Pitta, F, Rochester, CL, et al. An official European Respiratory Society statement on physical activity in COPD. Eur Respir J 44 (2014), 1521–1537.
79. Watz, H, Waschki, B, Meyer, T, Magnussen, H, Physical activity in patients with COPD. Eur Respir J 33 (2009), 262–272.
80. Spruit, MA, Pitta, F, McAuley, E, ZuWallack, RL, Nici, L, Pulmonary rehabilitation and physical activity in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 192 (2015), 924–933.
81. Beeh, KM, Watz, H, Puente-Maestu, L, et al. Aclidinium improves exercise endurance, dyspnea, lung hyperinflation, and physical activity in patients with COPD: a randomized, placebo-controlled, crossover trial. BMC Pulm Med, 14, 2014, 209.
82. Watz, H, Mailander, C, Baier, M, Kirsten, A, Effects of indacaterol/glycopyrronium (QVA149) on lung hyperinflation and physical activity in patients with moderate to severe COPD: a randomised, placebo-controlled, crossover study (the MOVE Study). BMC Pulm Med, 16, 2016, 95.
83. Watz, H, Krippner, F, Kirsten, A, Magnussen, H, Vogelmeier, C, Indacaterol improves lung hyperinflation and physical activity in patients with moderate chronic obstructive pulmonary disease—a randomized, multicenter, double-blind, placebo-controlled study. BMC Pulm Med, 14, 2014, 158.
84. Wen, CP, Wai, JP, Tsai, MK, et al. Minimum amount of physical activity for reduced mortality and extended life expectancy: a prospective cohort study. Lancet 378 (2011), 1244–1253.
85. Demeyer, H, Burtin, C, Hornikx, M, et al. The minimal important difference in physical activity in patients with COPD. PLoS One, 11, 2016, e0154587.
86. Spruit, MA, Singh, SJ, Garvey, C, et al. An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med 188 (2013), e13–e64.
87. Casaburi, R, ZuWallack, R, Pulmonary rehabilitation for management of chronic obstructive pulmonary disease. N Engl J Med 360 (2009), 1329–1335.
88. Puhan, MA, Gimeno-Santos, E, Scharplatz, M, Troosters, T, Walters, EH, Steurer, J, Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev, 2011 CD005305.
89. Rochester, CL, Vogiatzis, I, Holland, AE, et al. An Official American Thoracic Society/European Respiratory Society Policy Statement: enhancing implementation, use, and delivery of pulmonary rehabilitation. Am J Respir Crit Care Med 192 (2015), 1373–1386.
90. Vogelmeier, C, Hederer, B, Glaab, T, et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med 364 (2011), 1093–1103.
91. Decramer, ML, Chapman, KR, Dahl, R, et al. Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study. Lancet Respir Med 1 (2013), 524–533.
92. Wedzicha, JA, Calverley, PM, Seemungal, TA, Hagan, G, Ansari, Z, Stockley, RA, The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 177 (2008), 19–26.
93. Rabe, KF, Fabbri, LM, Israel, E, et al. Effect of ADRB2 polymorphisms on the efficacy of salmeterol and tiotropium in preventing COPD exacerbations: a prespecified substudy of the POET-COPD trial. Lancet Respir Med 2 (2014), 44–53.
94. Wedzicha, JA, Decramer, M, Ficker, JH, et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir Med 1 (2013), 199–209.
95. Singh, D, Papi, A, Corradi, M, et al. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting beta2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. Lancet 388 (2016), 963–973.
96. Magnussen, H, Disse, B, Rodriguez-Roisin, R, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med 371 (2014), 1285–1294.
97. Pascoe, S, Locantore, N, Dransfield, MT, Barnes, NC, Pavord, ID, Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med 3 (2015), 435–442.
98. Siddiqui, SH, Guasconi, A, Vestbo, J, et al. Blood Eosinophils: a biomarker of response to extrafine beclomethasone/formoterol in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 192 (2015), 523–525.
99. Watz, H, Tetzlaff, K, Wouters, EF, et al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. Lancet Respir Med 4 (2016), 390–398.
100. Lahousse, L, Verhamme, KM, Stricker, BH, Brusselle, GG, Cardiac effects of current treatments of chronic obstructive pulmonary disease. Lancet Respir Med 4 (2016), 149–164.
101. Nannini, LJ, Lasserson, TJ, Poole, P, Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev, 2012 CD006829.
102. Crim, C, Calverley, PM, Anderson, JA, et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur Respir J 34 (2009), 641–647.
103. Crim, C, Dransfield, MT, Bourbeau, J, et al. Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD. Ann Am Thorac Soc 12 (2015), 27–34.
104. Finney, L, Berry, M, Singanayagam, A, Elkin, SL, Johnston, SL, Mallia, P, Inhaled corticosteroids and pneumonia in chronic obstructive pulmonary disease. Lancet Respir Med 2 (2014), 919–932.
105. Pavord, ID, Lettis, S, Anzueto, A, Barnes, N, Blood eosinophil count and pneumonia risk in patients with chronic obstructive pulmonary disease: a patient-level meta-analysis. Lancet Respir Med 4 (2016), 731–741.
106. Woodruff, PG, Agusti, A, Roche, N, Singh, D, Martinez, FJ, Current concepts in targeting chronic obstructive pulmonary disease pharmacotherapy: making progress towards personalised management. Lancet 385 (2015), 1789–1798.
107. Fabbri, LM, Calverley, PM, Izquierdo-Alonso, JL, et al. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet 374 (2009), 695–703.
108. Martinez, FJ, Calverley, PM, Goehring, UM, Brose, M, Fabbri, LM, Rabe, KF, Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. Lancet 385 (2015), 857–866.
109. Martinez, FJ, Rabe, KF, Sethi, S, et al. Effect of roflumilast and inhaled corticosteroid/long-acting beta2-agonist on chronic obstructive pulmonary disease exacerbations (RE(2)SPOND). A randomized clinical trial. Am J Respir Crit Care Med 194 (2016), 559–567.
110. Albert, RK, Connett, J, Bailey, WC, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med 365 (2011), 689–698.
111. Han, MK, Tayob, N, Murray, S, et al. Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. Am J Respir Crit Care Med 189 (2014), 1503–1508.
112. Decramer, M, Rutten-van Molken, M, Dekhuijzen, PN, et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial. Lancet 365 (2005), 1552–1560.
113. Zheng, JP, Wen, FQ, Bai, CX, et al. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial. Lancet Respir Med 2 (2014), 187–194.
114. Barnes, PJ, Hansel, TT, Prospects for new drugs for chronic obstructive pulmonary disease. Lancet 364 (2004), 985–996.
115. Martinez, FJ, Donohue, JF, Rennard, SI, The future of chronic obstructive pulmonary disease treatment—difficulties of and barriers to drug development. Lancet 378 (2011), 1027–1037.
116. Watz, H, Barnacle, H, Hartley, BF, Chan, R, Efficacy and safety of the p38 MAPK inhibitor losmapimod for patients with chronic obstructive pulmonary disease: a randomised, double-blind, placebo-controlled trial. Lancet Respir Med 2 (2014), 63–72.
117. Brightling, CE, Bleecker, ER, Panettieri, RA Jr, et al. Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study. Lancet Respir Med 2 (2014), 891–901.
118. Rennard, SI, Dale, DC, Donohue, JF, et al. CXCR2 antagonist MK-7123. A phase 2 proof-of-concept trial for chronic obstructive pulmonary disease. Am J Respir Crit Care Med 191 (2015), 1001–1011.
119. Franciosi, LG, Diamant, Z, Banner, KH, et al. Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials. Lancet Respir Med 1 (2013), 714–727.
120. Watz, H, Mistry, SJ, Lazaar, AL, Safety and tolerability of the inhaled phosphodiesterase 4 inhibitor GSK256066 in moderate COPD. Pulm Pharmacol Ther 26 (2013), 588–595.
121. Shah, PL, Herth, FJ, van Geffen, WH, Deslee, G, Slebos, DJ, Lung volume reduction for emphysema. Lancet Respir Med 5 (2016), 147–156.
122. Herth, FJ, Slebos, DJ, Rabe, KF, Shah, PL, Endoscopic lung volume reduction: an expert panel recommendation. Respiration 91 (2016), 241–250.
123. Sciurba, FC, Criner, GJ, Strange, C, et al. Effect of endobronchial coils vs usual care on exercise tolerance in patients with severe emphysema: the RENEW randomized clinical trial. JAMA 315 (2016), 2178–2189.
124. Sciurba, FC, Ernst, A, Herth, FJ, et al. A randomized study of endobronchial valves for advanced emphysema. N Engl J Med 363 (2010), 1233–1244.
125. Herth, FJ, Valipour, A, Shah, PL, et al. Segmental volume reduction using thermal vapour ablation in patients with severe emphysema: 6-month results of the multicentre, parallel-group, open-label, randomised controlled STEP-UP trial. Lancet Respir Med 4 (2016), 185–193.
126. Shah, PL, Slebos, DJ, Cardoso, PF, et al. Bronchoscopic lung-volume reduction with Exhale airway stents for emphysema (EASE trial): randomised, sham-controlled, multicentre trial. Lancet 378 (2011), 997–1005.
127. The Long-Term Oxygen Treatment Trial Research Group. A randomized trial of long-term oxygen for COPD with moderate desaturation. N Engl J Med 375 (2016), 1617–1627.
128. Ekstrom, M, Clinical usefulness of long-term oxygen therapy in adults. N Engl J Med 375 (2016), 1683–1684.
129. Kohnlein, T, Windisch, W, Kohler, D, et al. Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease: a prospective, multicentre, randomised, controlled clinical trial. Lancet Respir Med 2 (2014), 698–705.
130. Vestbo, J, Anderson, JA, Brook, RD, et al. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet 387 (2016), 1817–1826.
131. Stone, IS, Barnes, NC, James, WY, et al. Lung deflation and cardiovascular structure and function in chronic obstructive pulmonary disease. A randomized controlled trial. Am J Respir Crit Care Med 193 (2016), 717–726.
132. White, WB, Cooke, GE, Kowey, PR, et al. Cardiovascular safety in patients receiving roflumilast for the treatment of COPD. Chest 144 (2013), 758–765.
133. Wouters, EF, Bredenbroker, D, Teichmann, P, et al. Effect of the phosphodiesterase 4 inhibitor roflumilast on glucose metabolism in patients with treatment-naive, newly diagnosed type 2 diabetes mellitus. J Clin Endocrinol Metab 97 (2012), E1720–E1725.
134. Gross, NJ, Barnes, PJ, New therapies for asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 195 (2017), 159–166.
135. Wedzicha, JA, Seemungal, TA, COPD exacerbations: defining their cause and prevention. Lancet 370 (2007), 786–796.
136. Hartl, S, Lopez-Campos, JL, Pozo-Rodriguez, F, et al. Risk of death and readmission of hospital-admitted COPD exacerbations: European COPD Audit. Eur Respir J 47 (2016), 113–121.
137. Leuppi, JD, Schuetz, P, Bingisser, R, et al. Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial. JAMA 309 (2013), 2223–2231.
138. Rohde, GG, Koch, A, Welte, T, Randomized double blind placebo-controlled study to demonstrate that antibiotics are not needed in moderate acute exacerbations of COPD—the ABACOPD study. BMC Pulm Med, 15, 2015, 5.
139. MacDonald, MI, Shafuddin, E, King, PT, Chang, CL, Bardin, PG, Hancox, RJ, Cardiac dysfunction during exacerbations of chronic obstructive pulmonary disease. Lancet Respir Med 4 (2016), 138–148.
140. Wedzicha, JA, Miravitlles, M, Hurst, JR, et al. Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J, 49, 2017, 1600791.
141. Suissa, S, Dell'Aniello, S, Ernst, P, Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax 67 (2012), 957–963.